Медуллобластома у детей. Клиника, диагностика, лечение, нерешенные проблемы

Медуллобластома у детей. Клиника, диагностика, лечение, нерешенные проблемы

Автор: Шонус Дарья Харлампиевна, Щербенко Олег Ильич

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 3 т.13, 2013 года.

Бесплатный доступ

В настоящем обзоре мы рассматриваем эпидемиологию, клинические проявления, диагностику и лечение медуллобластомы у детей. Особое внимание уделяется послеоперационной лучевой терапии в комбинации с химиотерапией, а также лечению медуллобластом у детей младшего возраста. Рассмотрены осложнения, возникающие при проведении химио-лучевого лечения медуллобластом у детей. Полученные данные при анализе литературы свидетельствуют о достаточно высокой вероятности достижения стойкой ремиссии у пациентов с локализованным процессом, но при распространенном процессе результаты лечения хуже. Таким образом, при лечении пациентов, входящих в высокую группу риска по возникновению метастазов медуллобластомы, требуется совершенствование методик лучевой и химиотерапии с возможным пересмотром используемых в настоящее время подходов в плане интенсификации воздействия на зоны риска рецидивирования опухоли. Совершенствование методов лечения должно базироваться на детальном анализе причин неудач и последствий используемых методов терапии.

Еще

Медуллобластома, диагностика, лучевая терапия, химиотерапия, осложнения

Короткий адрес: https://sciup.org/14955407

IDR: 14955407

Список литературы Медуллобластома у детей. Клиника, диагностика, лечение, нерешенные проблемы

  • Артарян А.А. Опухоли мозжечка у детей.//Москва, Медицина, 1979, с. 175.
  • Гальперин Э.К., Констайн Л.С., Тарбел Н.Д. и др. Лучевая терапия в детской онкологии.//Москва. Медицина, 1999, с. 748.
  • Голдобенко Г.В., Дурнов Л.А., Шароев Т.А. Руководство по детской онкологии.//Москва. Миклош, 2003, с. 504.
  • Желудкова О.Г., Бородина И.Д., Русанова М.Г., и др. Результаты комплексного лечения медуллобластом у детей старше 3-х лет высокой группы риска по протоколу М-2000. Тезисы/доклад, Материалы Первой Всероссийской Конференции по детской нейрохирургии, Москва, 18-20 июня 2003 г., с.37.
  • Желудкова О.Г., Бухны А.Ф., Лившиц М.И. Результаты комплексного лечения медуллобластом у детей с использованием ПХТ и лучевой терапии. Ступино, 7-9 декабря 1999 года, Материалы Российского конгресса "Новые технологии в неврологии и нейрохирургии на рубеже тысячелетий", с. 65.
  • Желудкова О.Г., Коршунов А.Г., Горбатых СВ. и др. Злокачественные тератоидрабдоидные опухоли центральной нервной системы у детей.//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2003. т 2, № 4, с. 32-39.
  • Желудкова О.Г. Практическое руководство по детским болезням. Гематология/онкология детского возраста под редакцией Румянцева А.Г., Самочатовой Е.В. МЕДПРАКТИКА-М, Москва 2004, т. 4., с.653-657.
  • Коршунов А.Г., Сычева А.В., Голанов А.В. Иммуногистохимическое изучение экспрессии онокассоциированых белков в медуллобластомах мозжечка.//Вопросы нейрохирургии. 1998. № 4. с. 8-13.
  • Личиницер М., Кирсанов А. Применение противорвотных препаратов при химиотерапии злокачественных опухолей.//Москва. 1996. Европейская школа по онкологии. Сб. «Поддерживающая терапия у онкологических больных».
  • Мацко Д.Е., Коршунов А.Г. Атлас опухолей центральной нервной системы.//СПб. 1998. с. 76-80.
  • Переводчикова Н.И. Противоопухолевая химиотерапия. Справочник.//Москва. 2003. с. 221.
  • Холодов Б.В., Бухны А.Ф., Желудкова О.Г. и др. Роль химиотерапии в комплексном лечении опухолей головного мозга у детей.//Педиатрия. 1995. № 2. с. 91.
  • Хухлаева Е.А., Раевская С.А., Комаров В.И. и др. Злокачественные опухоли головы и шеи.//Медицина, Москва, 1993, с. 45.
  • Черствый Е.Д., Кравцова Г.И., Фурманчук А.В. Опухоли и опухолеподобные процессы у детей.//«Асар», Минск, 2002, с. 81-125.
  • Щербенко О.И., Говорина Е.В. Радиационные повреждения головного мозга после лучевой терапии опухолей ЦНС.//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2003, т.2, № 3, с.40-43
  • Albright A.L., Wisoff J.H., Zeltzer P.M. et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's cancer Group.//Neurosurgery. 1996. V. 38. P. 265-271.
  • Aldosari N., Bigner S.H., Burger P.C. et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.//Arch Pathol Lab Med. 2002. V. 126. P. 540-544.
  • Allen J.C. Complications of chemotherapy in patients with brain and spinal cord tumors. Pedi-atr-Neurosurg. 1991-92, V. 17. N 4. P. 218-224.
  • Allen J.C., Donahue В., Da Rosso R., Nierenberg A. Hypofractionated craniospinal radiotherapy and adjuvant chemotherapy for children with primitive neuroectodermal tumors.//Int J Radiat Oncol Biol Phys. 1996. V. 30. P. 1155-61.
  • Bailey C., Gnekow A., Wellek S. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma: SIOP and GPO-SIOPII.//Med Pediatr Oncol. 1995. V. 25. P. 166-178.
  • Balis F. Concepts and physiological underpinnings of intrathecal chemotherapy. SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany, October 2-6. 2008. S.063. P. 13.
  • Bannering В., Rutkowski S., Gustafsson G. et al. HIT-SIOP PNET 4 multicentre study of hyperfractionated versus conventional RT in standard risk medulloblastoma.//SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany. October 2-6. 2008. O. 098. P. 45-46.
  • Bayani J., Zielenska M., Marrano P. et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping.//J Neurosurg. 2000. V. 93. P. 437-448.
  • Becker L.E., Giangaspero F., Rorke L.B. et al. Embryonal tumours. In: Kleihues P., Cavenee W.K., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 2000. P. 123-148.
  • Bergman M., Pietsch T., Herms J. Medulloblastoma: a histological, immunohistochemical, ultrastructural and molecular genetic study.//Acta Neuropathologica, 1998, Abstract V. 95 Issue 2, P. 205212.
  • Biegel J.A., Janss A.J., Raffel С. et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.//Clin Cancer Res 1997. V. 3. P. 473-478.
  • Biegel J.A. Cytogenetics and molecular genetics of childhood brain tumors.//Neurooncol. 1999. V. 1. P. 139-151.
  • Bilsky M.H., Lis E. The diagnosis and treatment of metastatic spinal tumor.//The Oncologist. 1999. V. 4. P. 456-469.
  • Blaney S.M., Poplack D.G. New cytotoxic drugs for intrathecal administration.//J Neuro-Oncol. 1998. V. 38. P. 219-23.
  • Borgwardt L., Hojgaard L., Carstensen H. et al. Increased fluorine-18 2-fluoro-2-deoxy-d-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG
  • positron emission tomography/magnetic resonance imaging coregistration and image fusion.//J Clin Oncol. 2005. V. 23. P. 3030-3037.
  • Bouffet E., Gentet J.C., Chastagner P. et al. High dose chemotherapy with autologous bone marrow rescue in childhood brain gliomas and ependimomas: an EBMT report. SIOP XXV Meeting. 1993. P. 563.
  • Bourne J.P., Geyer R., Berger M., et al. The prognostic significance of postoperative residual enhancement on CT scan in pediatric patients with medulloblastoma.//J Neuro-Oncol. 1992. V. 14. P. 263-70.
  • Brown H.G., Kepner J.L., Perlman E.J. et al: "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study.//J Neuropathol Exp Neurol. 2000. V. 59. P. 857-865.
  • Carlos A., Luther W. “Principles and practice of radiation oncology”. J.B. Lippincott, Philadelphia. 1992. P. 1544.
  • Carrie C., Alapetite C., Mere P. et al. Quality control of radiotherapyeutic treatment of medulloblastoma in a multicentric study: the contribution of radiotherapy technique to tumor relapse. The French Medulloblastoma Group.//Radiother Oncol. 1992. V. 24. P. 77-81.
  • Carrie C., Hoffsteller S., Gomes F. et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).//Int J Radiat Oncol Biol Phys. 1999. V. 45. P. 435-9.
  • Catsman-Berrevoets C.E., Van Donegan H.R., Mulder P.G. et al. Tumour type and size are high risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria.//J Neurol Neurosurg Psychiatry. 1999. V. 67. P. 755-757.
  • Cefalo G., Gandola L., Luksch R. Adjuvant high-dose sequential chemotherapy plus hyperfractionated radiotherapy in childhood medulloblastoma. SIOP-ASPH/O MEETING, Canada, Montreal, 1318 Sept, 1999, Abst., P. 31, 204.
  • Central Brain Tumors Registry of the United States (CBTRUS) Statistical report 2004-2005, www.cbtrus.org
  • Chan K.W., Fryer C.J., Steinbok P. Modification of the 8 drugs in 1 day regimen.//J Neurooncol. 1990. Oct; V. 9; N 2: P. 153-7.
  • Chang C.H., Housepian E.M., Herbert C. An operative system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas.//Radiology. 1969. V. 93. P. 1351-9.
  • Chi S.N., Gardner S.L., Levy A.S. et al. Feasibility and Response to Induction Chemotherapy In tensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma.//J. Clin Oncol. 2004. V. 22. P. 4881-4887
  • Christensen V., McDonough J., Tochner Z. Proton beam irradiation in pediatric oncology an overview.//J Ped Hematol Oncol. 2005. V27; N8: P. 444-448.
  • Clerico A., Cappelli С Schiavetti A. Adjuvant chemotherapy in medulloblastoma patients:
  • single institution experience. SIOP-ASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abs., P. 32, 204.
  • Cochrane D.D., Gustavsson B., Poskitt K.P. et al. The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood.//Pediatr Neurosurg 1994; V. 20. P. 19-29
  • Cohen M.S., Duffner P. "Brain tumors in children. Principles of diagnosis and treatment" Raven Press New York, 1994.
  • Cohen В., Zeltzer P., Boyett J. et al. Prognostic factors and treatment results for primitive neuroectodermal tumors in children using radiation and chemotherapy: a Children's Cancer Group Randomized Trial.//J Clin Oncol 1996. V. 13. P. 1687-96.
  • Crofton P., Ahmed S., Wade J. et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.//J Clin Endocrinol Metab. 1998. V. 83. P. 3121-9.
  • Deutch M., Thomas P.R.M., Krischer J. Results of a prospective randomized trial comparing standart dose neuraxis irradiation (3,600 cGy/20) with redused neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A combined Childrens Cancer Group-Pediatric Oncology Group Study.//Pediatr Neurosurg. 1996. V. 24. P. 167-177.
  • Deutsch M. Medulloblastoma: staging and treatment outcome.//Int J Radiat Oncol Biol Phys. 1988;14:1103-1107.
  • Fouladi M., Heideman R., Langston J.W. et al. Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging.//J Neurosurg. 1999. V. 91. P. 499-502.
  • Dieckmann K., Kren G., Schuller E. et al. Fractionated Stereotactic radiotherapy of residual or recurrent brain tumors in children after conventional radiotherapy. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, SL-54,P. 188.
  • Duffner P.K., Cohen M.E. Long-term consequences of CNS treatment for childhood cancer, Part II: Clinical Consequences.//Pediatr-Neurol. 1991. V. 7. N. 4. P. 237-42.
  • Duffner P.K., Horowitz M.E., Krischer J.P. et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.//N Engl J Med. 1993. V. 328. P. 1725-1731.
  • Duffner P.K., Horowitz M.E., Krischer J.P. et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience.//J Neuro-Oncol. 1999. V. 1. P. 152-61.
  • Duffner P.K., Krischer J.P., Horowitz M.E., et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group Study.//Ann Neurol. 1998. V. 44. P. 313-316.
  • Dunkel I.J., Boyett J.M., Yates A. et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.//J
  • Clin Oncol. 1998. V. 16. P. 222-228.
  • Dupus-Girod S., Hartman O., Benhamon E. et al. Will high-dose chemotherapy followed by autologus bone marrow transplantation supplant craniospinal irradiation in young children treated for medulloblastoma.//J Neurooncol. 1996. V. 27. P. 87-98.
  • Eberhart C.G., Kratz J.E., Schuster A. et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.//Brain Pathol. 2002. V. 12. P. 36-44.
  • Ellison D.: Classifying the medulloblastoma: Insights from morphology and molecular genetics.//Neuropathol Appl Neurobiol. 2002. V. 28. P. 257-282.
  • Ellison D.W., Clifford S.C., Gajjar A., et al: What's new in neuro-oncology? Recent advances in medulloblastoma.//Eur J Paediatr Neurol. 2003. V. 7. P. 53-66.
  • Evans A.E., Jenkin R.D.T., Sposto R. et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone.//J Neurosurg. 1990. V. 72. P. 572-82.
  • Ferencz T., Csaki Cs. Combined adjuvant chemotherapy in malignant pediatric brain tumors -preliminary results.//Medical and Pediatric Oncology. November 1997. V. 29. N5, Abstr. P. 113, 416.
  • Flores L.E., Williams D.L., Bell A.B. et al. Delay in the diagnosis of pediatric brain tumors.//Am J Child. 1986. V. 140. P. 684-686.
  • Fouladi M. et al. A Phase I., molecular biology and phase II study lapatinib (GW572016) in pediatric patients with recurrent or refractory medulloblastoma, malignant glioma or ependymoma. PBTC-016, 10/11/2004.
  • Fruhwald M.C., O'Dorisio M.S., Dai Z. et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p 11.2 in medulloblastomas but not supratentorial PNETs.//Genes Chromosomes Cancer. 2001. V. 30. P. 38-47.
  • Gajjar A., Fouladi M., Walter A. Comparison of lumbar and shunt CFS for cytologyc detection of leptomeningeal disease in pediatric patients with brain tumors.//J Clin Oncol. 1999. V. 17. N6. P. 1825-1828.
  • Gajjar A. Recent advances in therapy for medulloblastoma. U.S.A., ASCO//J Clin Оncol. 1999. P. 579-586.
  • Gajjar A., Hernan R., Kocak M. Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma.//J Clin Oncol. 2004. V. 22. P. 984-993.
  • Gentet J.C., Bouffet E., Doz F. et al. Preirradiation chemotherapy including "eight drugs in one day" regimen and high-dose metotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.//J Neurosurg. 1995. V. 82. P. 608-614.
  • Geyer J.R., Zeltzer P.M., Boyett J.M. et al. Survival of infants with primitive Neuroectodermal
  • tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Children's Cancer Group.//J Clin Oncol. 1994. V. 12. P. 1607-15.
  • Geyer R., Jennings M., Boyett J. et al. Chemotherapy in infants with malignants brain tumors. ASCO. 1998. Abstr. P. 2019
  • Giangaspero F., Chieco P., Ceccarelli C. et al. "Desmoplastic" versus "classic" medulloblastoma: comparison of DNA content, histopathology and differentiation.//Virchows Arch A Pathol Anat Histopathol. 1991. V. 418. P. 207-214.
  • Gilbertson R. Paediatric embryonic brain tumours: Biological and clinical relevance of molecular genetic abnormalities.//Eur J Cancer. 2002. V. 38. P. 675-685.
  • Gilbertson R.J., Clifford S.C., MacMeekin W. et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implifications for the biology of medulloblastoma.//Cancer Res. 1998. V. 58. P. 3932-41.
  • Gilbertson R.J., Pearson A.D., Perry R.H. et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.//Br J Cancer. 1995. V. 71. P. 473-477.
  • Gilbertson R.J., Wickramasignghe C., Herman R. et al. Clinical and molecular stratification of disease risk in medulloblastoma.//Br J Cancer. 2001. V. 85. P. 705-712.
  • Giller C., Berger В., Pistenmaa D. et al. Robotically guided radiosurgery for children.//Ped Blood Cancer. 2005. V. 45. P. 304-310.
  • Glauser T.A., Packer R.J. Cognitive deficits in long term survivors of childhood brain tumors. U.S.A.//Child's Nervous System. 1991. V. 7. P. 2-12.
  • Gnekow A. Reccomendations of the Brain Tumor Subcommittee for the reporting of the trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology.//Med Pediatr Oncol. 1995. V. 24. P. 104-108.
  • Gold D.R., Packer R.J., Cohen B.H. et al. Treatment strategies for medulloblastoma and primitive neuroectodermal tumors.//Neurosurg Focus, 1999, V7(2): e1.
  • Golomb L., Johnson J., Dunkel I., Halpern S. Chemotherapy only for young children with newly diagnosed malignant brain tumors: an update on the "Head Start" regimen. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999. Abstract. P. 18, 201.
  • Grotzer M.A., Hogarty M.D., Janss A.J. et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.//Clin Cancer Res. 2001. V. 7. P. 2425-2433.
  • Grotzer M.A., Janss A.J., Fung К. et al. TrkC expression Hinkes B.G., von Hoff K., Deinlein F., Warmuth-Metz M., et al. Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91.//J Neurooncol. 2007. V. 81. P. 217-223
  • Hart M.N., Early K.M. Primitive neuroectodermal tumors of the brain in children.//Cancer 1973. V. 32. P. 890-897.
  • Heideman R.L., Packer R.J., Albright L.A. et al. Tumors of the Central Nervous System. U.S.A. 1987. P. 505-547.
  • Herms J., Neidt I., Luscher B. et al: C-MYC expression in medulloblastoma and its prognostic value.//Int J Cancer 2000.V. 89. P. 395-402.
  • Hinkes B.G., von Hoff K., Deinlein F., Warmuth-Metz M. et al. Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91.//J Neurooncol. 2007. V. 81. P. 217-223.
  • Hong T.S., Mehta M.P., Boyett J.M. et al. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study.//Ped Boold Cancer. 2005. V. 45. P. 676-682.
  • Howell R.M., Giebel A., Koontz-Raisig W. et all Comparison of therapeutic dosimetric data from passivly scattered proton and photon craniospinal irradition for medulloblastoma.//Radiat oncol. 2012. V. 24. N.7. P. 116.
  • Hyder D.J., Butturini A.M., Anderson C.P. High dose chemotherapy and autologous stem cell transplant for pediatric malignant brain tumors. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, P.19, 201.
  • Ilveskoski I., Saarinen U.M., Wiklund T. Growth impairment and growth hormone therapy in children treated for malignant brain tumors.//European Journal of Pediatrics, 1997. Abstract. V. 156 I10, P. 764-769.
  • Jakacki R., Schramm C., Donahue В. et al. Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation.//J Clin Oncol. 1995. V. 13. P. 1478-1485.
  • Jakacki R., Zeltzer P., Boyett J., Albright L. et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Children's Cancer Group.//J Clin Oncol. 1995. V. 13. P. 1377-83.
  • Jenkin D., Shabanah M. Al, Shail E. Al, et al. Medulloblastoma. Prognostic factors. SIOPASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abstract, V. 27. P. 279.
  • Jenkin D.K., Goddard D., Armstrong L. et al. Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system.//Int J Radiat Oncol Biol Phys. 1990. V. 19. P. 265-74.
  • Johnston D., Daniel L., Keene L., Lafay-Cousin L. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report.//J Neurooncol. 2007. DOI 10.1007/sl 1060 007-9440-1.
  • Jones B., Wilson P., Nagano A. et all. Dillemas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.//Br J Radiol. 2012 Oct: 85 (1018): t 912-8.
  • Kalapurakal J.A., Goldman S., Hsieh Y.С. Long term results of hyper fractionated craniospinal
  • radiation in medulloblastoma.//SIOP-ASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abstract, P. 52, 208.
  • Kalifa C., Grill J. The therapy of infantile malignant brain tumors: current status.//J Neuro-Oncol. 2005. V. 75. P. 279-285.
  • Khong P., Leung L., Fung A. et al. White matter anisotropy in post-treatment childhood cancer survivors: preliminary evidence of association with neurocognitive function.//J Clin Oncol. 2006. V. 24. P. 884-890.
  • Kieffer-Renaux V., Viguier D., Raqune M.A. et al. Therapeutic schedueles influence the pattern of intellectual decline after irradiation of posterior fossa tumors.//Ped Blood Cancer. 2005. V. 45. P. 814-819.
  • Kim J.Y., Sutton M.E., Lu D.J. et al. Activation of neurotrophin-3 receptor TrkC induces apop-tosis in medulloblastomas.//Cancer Res. 1999. V. 59. P. 711-719.
  • Kortmann R.D., Kuhl J., Timmermann В. et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.//Int J Radiat Oncol Biol Phys. 2000. V. 46. P. 269-279
  • Krischer J.P., Ragab A., Kun L. et al. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma.//J Neurosurg. 1991. N. 74. P. 905 9.
  • Kuhl J., Bode U., Deinlein F., Ottensmeier H. Cure of infants with medulloblastoma (МО/MI stage) by postoperative chemotherapy only.//SIOP-ASPH/O MEETING, Canada, Monreal, 13-18 Sept, 1999, Abstract, P107, 169.
  • Kuhl J., Doz F., Taylor R. Embryonic tumors. Walker D.A., Perilongo G., Punt J.A.G., Taylor R.E., eds. Brain and spinal Tumors of childhood.//Arnold, New York. 2004: P. 314-330, 436.
  • Kuhl J., Muller H.L., Berthold F. et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German Pilot trial HIT'88/89.//Klin Padiatr. 1998. Jul-Aug. V. 210. N. 4. P. 227-33.
  • Kuhl J., Gnekow A., Havers W. et al. Primary chemotherapy after surgery and delayed irradia tion in children under three years of age with medulloblastoma -pilot trial of the German Pediatric Brain Tumor Study Group. Protocol HIT-91, 1991.
  • Kumar R., Achari G., Banerjee D. et al. Uncommon presentation of medulloblastoma.//Childs Nerv Syst. 2001; N. 17: P. 538-542; discussion 543
  • Kun L.E. Brain tumors in infants and young children. U.S.A, ASCO.//J Clin Oncol. 1999. P. 574-578.
  • Laurent J.P., Chang C.H., Cohen M.E. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa.//Cancer. 1985. V. 56 (7 Suppl). P. 1807-1809.
  • Lee M., Wisoff J.H., Abbott R. et al. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting.//Pediatr Neurosurg. 1994. V. 2: P. 240-247.
  • Louis D., Cavenee W., Ohgaki H. World Health Organization classification of tumors of the central nervous system. 4lh Edition. Lyon, France: International Agency for Research on Cancer. 2007. P. 8-11, 132-149.
  • MacDonald T.J., Brown K.M., LaFleur В. et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.//Nat Genet. 2001. V. 29: P. 143-152
  • Marymont M.R., Geohas J., Tomita Т. et al. Hyperfractionated craniospinal radiation in medulloblastoma.//Pediatr Neurosurg. 1996; V. 24: P. 178-84.
  • Meyers C.A., Brown P. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.//J of Clin Oncol. 2006. V. 24. N8. P. 1305-9.
  • Michalski J. et al. A Study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18,0 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: a Phase III double randomized trial. 09/10/04, P. 1-92.
  • Milde Т., Oehme I., Pfiser S. et al. Histone deacetylases 5 and 9 are novel markers for medulloblastoma risk stratification and potential drug targets for therapy. SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany. October 2-6. 2008. O.096. P. 45.
  • Mirabell R., Bieri S. Medulloblastoma staging: is the cerebrospinal fluid cytology a reliable prognostic factor.//Medical and Pediatric Oncology. November 1997. V. 29. N. 5. Abstr. P. 61, 401.
  • Mirabell R., Bieri S., Huguenin P. et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group.//Ann Oncol. 1999. V. 10. P. 239-41.
  • Mosijczuk A.D., Nigra M.A., Thomas P.R.M. et al. Pre-irradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group Pilot Study.//Cancer. 1993. V. 72. P. 2755-62.
  • Mulherm R.K., Reddick W.E., Elkin T.D. Neurocognitive deficits in medulloblastoma survivors are associated with white matter loss.//Medical and Pediatric Oncology. November 1997. V. 29. N. 5. Abstr. P. 173, 365.
  • Norris L.S., Snodgrass S., Miller D.C. et al. Recurrent central nervous system medulloepithelioma: response and outcome following marrow-ablative chemotherapy with stem cell rescue.//J Pediatr Hematol Oncol. 2005. V. 27. P. 264-266.
  • Ogilvy-Stuart A., Clayton P., Shalet S. Cranial irradiation and early puberty.//J Clin Endocrinol Metab. 1994. V. 78. P. 1282-6.
  • Oyharcabal-Bourden V., Kalifa C., Gentet J.C. et al. Standard risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French society of pediatric oncology study.//J Clin Oncol. 2005. V. 23. P. 4726-34.
  • Packer R. Brain tumors in children.//Arch Neurol. 1999.V. 56. P. 421-425.
  • Packer R., Boyett J., Janns A. et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control.//J Clin Oncol. 2001. V. 19. P. 480-7.
  • Packer R.J. Progress and challenges in childhood brain tumors.//J of Neuro-Oncol. 2005. V.75. P. 239-42.
  • Packer R.J., Goldwein J., Nicholson H.S. et al. Treatment of children with medulloblastoma with reduced dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study.//J Clin Oncol. 1999. V. 17. P. 2127-36.
  • Packer R.J., Sutton L.N., Elterman R. et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy.//J Neurosurg. 1994.V. 81. P. 690-698.
  • Packer R.J., Cogen P., Vezina G. et al. Medulloblastoma: clinical and biologic aspects.//Neurooncol. 1999. V. 1. P. 232-250.
  • Paulino A.C., Wen B.C., Mayr N.A. et al. Protracted radiotherapy treatment duration in medulloblastoma.//Am J Clin Oncol. (CCT) 2003. V. 26. N. 1. P. 55-59.
  • Pietsch T. Molecular pathogenesis of embryonal tumors: loss of developmental control. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, SL-56, 188.
  • Pollack I.F., Polinko P., Albright A.L. et al. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology.//Neurosurgery. 1995. V. 37. P. 885-893.
  • Prados M.D., Edwards M.S., Chang S.M. et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a phase II study.//Int J Radiat Oncol Biol Phys. 1999. V. 43. P. 279-85.
  • Prityko A., Kholodov B., Geludkova O. Hematological toxicity of chemotherapy in children with medulloblastoma. SIOP-ASPH/O MEETING, Canada, Montreal, 13-18 Sept, 1999, Abstract, P. 85, 294.
  • Probert J., Packer В., Kaplan H. Growth retardation in children after megavoltage irradiation of the spine.//Cancer. 1973. V. 32. P. 634-9.
  • Raffel C., Jenkins R.B., Frederick L. et al. Sporadic medulloblastomas contain PTCH mutations.//Cancer Res. 1997. V. 57. P. 842-845.
  • Reddy A.T., Janss A.J., Phillips P.C. et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation and chemotherapy.//Cancer. 2000. V. 88. P. 2189-2193.
  • Reddy A.T., Janss A.J., Phillips P.C. et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation and chemotherapy.//Cancer. 2000. V. 88. P. 2189-2193.
  • Ricardi U., Besenzon L., Cordero di Montezemolo L. et al. Low dose hyperfractionated craniospinal radiation therapy for childhood cerebellar medulloblastoma: Early results of phase I-II study.//European Journal of Cancer, 1997. Abstr. P. 911.
  • Rickert С.H. Abdominal metastases of pediatric brain tumors via ventriculo-peritoneal shunts.//Childs Nervous System. 1998. Abstract V. 14 I.1/2. P. 10-14.
  • Robinson G. Acute Neurologic dysfunction in Brain Tumor Patients undergoing autologous BMT. www.cure4kids.org 2008.
  • Rocco C.Di, Iarmelli A., Papacci F. et al. Prognosis of medulloblastoma in infants. Child's Nervous System. 1997. Abstract V. 13 I. 7. P. 388-396.
  • Roman D.D., Sperduto P.W. Neuropsychological effects of cranial radiation: current knowledge and future directions.//Int J Radiat Oncol Biol Phys. 1995. V. 31. P. 983-98.
  • Rorke L.B., Packer R.J., Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity.//J Neurosurg. 1996. V. 85. P. 56-65.
  • Rutka J.T., Hoffman H.J. Medulloblastoma: a historical perspective and overview.//J Neuro-Oncol. 1996. V. 29. P. 1-7.
  • Rutkowski S. Chemotherapeutic strategies for young children with brain tumors. SIOP Abstract Book, 40 th Congress of the SIOP, Berlin, Germany, October 2-6, 2008. S.026. P. 7.
  • Saran F.H., Driever P.H., Thilmann С. et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.//Int J Radiat Oncol Biol Phys. 1998. V. 42. P. 959-967.
  • Scheurlen W., Schwabe G., Kuhl J. Molecular markers predicting poor outcome in medulloblastoma and supratentorial PNET.//Medical and Pediatric Oncology. November 1997. V. 29. N.5. Abstr. 0-4, 316.
  • Schmiegelow M., Lassen S., Poulsen H.S. Long lasting growth hormone deficiency (GHD) following radiotherapy of a brain tumor in childhood abrogates the response to growth hormone releasing hormone. SIOP-ASPH/O MEETING. Canada, Monreal. 13-18 Sept. 1999. Abstract. 0-75, 162.
  • Segal R.A., Goumnerova L.C., Kwon Y.K. et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.//Proc Natl Acad Sci USA. 1994. V. 91. P. 12867-12871
  • Slampa P., Zitterbart K., Dusek L. et al. Craniospinal irradiation of medulloblastoma in the supine position.//Rep Pract Oncol Radiother. 2006. V. 11. N. 6. P. 265-272
  • Slave I., Schuller E., Czech T. et al. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.//J Neurooncol. 1998. V. 38. P. 213-218.
  • Smith M.A., Freidlin В., Ries L.A. et al. Trends in reported incidence of primary tumors in children in the United States. U.S.A.//J Nati Cancer Inst. 1998. V. 90. P. 1269-1277.
  • Stavrou Т., Nicholson H.S., Byrne J. et al. Genetic predisposition and second cancer in childhood medulloblastoma. ASCO. 1998. Abstr. 2166.
  • Strother D., Ashley D., Kellie S.J. et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem cell rescue for patients with newly diagnosed medulloblastoma or supratentorial PNET after craniospinal radiotherapy: results of a collaborative study.//J Clin Oncol. 2001. V. 19. N.10. P. 2696-2704.
  • Tait D.M., Thornton-Jones H., Bloom H.J.G., Lemerie J. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Pediatric Oncology (SIOP I),//Eur J Cancer. 1990. V. 26. P. 464-469.
  • Taylor R.E., Bailey C.C., Robinson K. et al. Results of randomized study of the preradiotherapy chemotherapy vs radiotherapy alone for non-metastatic (M0-1) medulloblastoma. The SIOP/UKCCSG PNET-3 study.//J Clin Oncol. 2003. V. 21. P. 1581-1591.
  • Thomas P.R., Deutsch M., Kepner J.L. et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuroaxis irradiation.//J Clin Oncol. 2000.V.18. P. 3004-3011.
  • Timmermann В., Kortmann R.D., Kuhl J. et al. Role of radiatiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT~SKK'87and HIT-SKK'92 trials.//J Clin oncol. 2006. V. 24. P. 1554-1560.
  • Tompson M., Fuller C., Hogg Т. et al. Genomic identifies medulloblastoma subgroups that are enriched for specific genetic alterations.//J Clin Oncol. 2006.V. 24. P. 1924-1931.
  • Uysal K.M., Sanalioglu F., Olgun N. Hemolitic anemia and capillary-leak syndrom in a patient with medulloblastoma who received carbo-platinum-based chemotherapy (SIOP/PNET III regimen).//Medical and Pediatric Oncology. November 1997. V. 29. N. 5. Abstr. 129, 490.
  • Wada C., Kurata A., Hirose R. et al. Primary leptomeningeal ependymoblastoma. Case report.//J Neurosurg. 1986. V. 64. P. 968-973.
  • Walker D.A., Perilongo G., Punt J.A.G., Taylor R.E. Brain and spinal Tumors of childhood. Arnold. New York. 2004. P. 324.
  • Walker R., Allen J., Rosen G. et al. Transient cerebral dysfunction secondary to high-dose methotrexate.//J Clin Oncol. 1986. V. 4. P. 1845-1850.
  • Watterson J., Simonton SC., Rorke L.B. et al. Fatal brain stem necrosis after standard posterior fosse radiation and aggressive chemotherapy for metastatic medulloblastoma.//Cancer. 1993. V. 71. N. 12. P. 4111-4117.
  • Wetmore C., Eberhart D.E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.//Cancer Res. 2001. V. 61. P. 513-516.
  • Wisoff J.H., Epstein F.J. Pseudobulbar palsy after posterior fossa operation in children. U.S.A.//Neurosergery. 1984. V. 15. P. 707-709.
  • Xu W., Janss A., Packer R., Phillips P. et al. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy.//Neuro-Oncol. 2004. V. 6. P. 113-118.
  • Yamada K., Yamashiro S., Itoyama Y. et al. Sinus thrombosis during CDDP and VP-16 (PE) therapy for suprasellar germ-cell tumor: case report.//No-Shinkei-Geka. 1993. V. 21. N. 11. P. 1025-9.
  • Yang Z.J. et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.//Cancer Cell. 2008. V. 14. P. 135-145.
  • Young S.W., Qing F., Harriman A. et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRJ.//Proc Natl Acad Sci USA. 1996. V. 93. P. 6610-6615.
Еще
Статья обзорная
SciUp 2024 © 2024 ©